Principia Biopharma (PRNB) – Research Analysts’ Recent Ratings Changes

Share on StockTwits

Several brokerages have updated their recommendations and price targets on shares of Principia Biopharma (NASDAQ: PRNB) in the last few weeks:

  • 10/9/2018 – Principia Biopharma is now covered by analysts at Robert W. Baird. They set an “outperform” rating on the stock.
  • 10/9/2018 – Principia Biopharma is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $34.00 price target on the stock.
  • 10/9/2018 – Principia Biopharma is now covered by analysts at Wells Fargo & Co. They set an “outperform” rating on the stock.
  • 10/9/2018 – Principia Biopharma is now covered by analysts at Bank of America Corp. They set a “buy” rating on the stock.

PRNB traded up $0.45 during trading on Friday, reaching $23.85. The stock had a trading volume of 62,300 shares, compared to its average volume of 89,273. Principia Biopharma Inc has a one year low of $22.00 and a one year high of $36.00.

In other news, major shareholder Leaf Ventures Ii L.P. New bought 270,000 shares of Principia Biopharma stock in a transaction that occurred on Tuesday, September 18th. The shares were acquired at an average price of $17.00 per share, with a total value of $4,590,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Srinivas Akkaraju bought 175,000 shares of Principia Biopharma stock in a transaction that occurred on Tuesday, September 18th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $2,975,000.00. The disclosure for this purchase can be found here.

Principia Biopharma Inc, a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome.

Read More: 52-Week High/Low

Receive News & Ratings for Principia Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.